Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral host, and environmental factors. Ann Intern Med. 2021;174:69–79.

Article  PubMed  Google Scholar 

Sussman RA, Golberstein E, Polosa R. Aerial Transmission of the SARS-CoV-2 Virus through Environmental E-Cigarette Aerosols: Implications for Public Policies. Int J Environ Res Public Health. 2021;18(4):1437. https://doi.org/10.3390/ijerph18041437.

Article  CAS  PubMed  PubMed Central  Google Scholar 

https://www.worldometers.info/coronavirus/. Accessed 10 Nov 2022.

Peiffer-Smadja N, Rebeaud ME, Guihur A, Mahamat-Saleh Y, Fiolet T. Hydroxychloroquine and COVID-19: a tale of populism and obscurantism. Lancet Infect Dis. 2021;21(5):e121. https://doi.org/10.1016/S1473-3099(20)30866-5.

Article  CAS  PubMed  Google Scholar 

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. RECOVERY Collaborative Group. Dexametasona en pacientes hospitalizados con Covid-19. 2021;384(8):693-704. https://doi.org/10.1056/NEJMoa2021436.

Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–18. https://doi.org/10.1016/S2213-2600(21)00331-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, et al. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021;326(6):499–518. https://doi.org/10.1001/jama.2021.11330.

Article  CAS  PubMed  Google Scholar 

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, ACTT-1 Study Group Members, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813–26. https://doi.org/10.1056/NEJMoa2007764.

Article  CAS  PubMed  Google Scholar 

Schumaker AH, Bhimraj A. Pharmacologic treatment and management of Coronavirus Disease 2019. Infect Dis Clin North Am. 2022;36(2):349–64. https://doi.org/10.1016/j.idc.2022.02.001.

Article  Google Scholar 

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–54. https://doi.org/10.1016/j.antiviral.2013.09.015.

Article  CAS  PubMed  Google Scholar 

Oestereich L, Lüdtke A, Wur RS, Rieger T, Rieger T, Muñoz-Fontela C, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17–21.

Article  CAS  PubMed  Google Scholar 

Bai CQ, Mu JS, Kargb OD, Song YB, Niu WK, Nie WM, et al. Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis. 2016;63(10):1288–94.

Article  PubMed  Google Scholar 

Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007;51:3168–76 PLoSNegl Trop Dis. 2011;5:e1342.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020;6(10):1192–8. https://doi.org/10.1016/j.eng.2020.03.007.

Article  CAS  PubMed  Google Scholar 

Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71.

Article  CAS  PubMed  Google Scholar 

https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/. Accessed 10 Nov 2022.

McMahon JH, Lau JSY, Coldham A, Roney J, Hagenauer M, Price S, et al. Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. EClinicalMedicine. 2022;20(54):101703. https://doi.org/10.1016/j.eclinm.2022.101703.

Article  Google Scholar 

Bosaeed M, Alharbi A, Mahmoud E, Alrehily S, Bahlaq M, Gaifer Z, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin Microbiol Infect. 2022;28(4):602–8. https://doi.org/10.1016/j.cmi.2021.12.026.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chuah CH, Chow TS, Hor CP, Cheng JT, Ker HB, Lee HG, Malaysian Favipiravir Study Group, et al. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized. Open-Label Clinical Trial Clin Infect Dis. 2022;75(1):e432–9. https://doi.org/10.1093/cid/ciab962. PMID: 34849615.

Article  CAS  PubMed  Google Scholar 

AlQahtani M, Kumar N, Aljawder D, Abdulrahman A, Mohamed MW, Alnashaba F, et al. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. Sci Rep. 2022;12(1):4925. https://doi.org/10.1038/s41598-022-08794-w. (Erratum in: Sci Rep. 2022 Sep 26;12(1):16052).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shinkai M, Tsushima K, Tanaka S, Hagiwara E, Tarumoto N, Kawada I, et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial. Infect Dis Ther. 2021;10(4):2489–509. https://doi.org/10.1007/s40121-021-00517-4.

Article  PubMed  PubMed Central  Google Scholar 

Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, et al. Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study. Emerg Microbes Infect. 2022;11(1):2197–206. https://doi.org/10.1080/22221751.2022.2117092.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah PL, Orton CM, Grinsztejn B, Donaldson GC, Crabtree Ramírez B, Tonkin J, Santos BR, Cardoso SW, Ritchie AI, Conway F, Riberio MPD, Wiseman DJ, Tana A, Vijayakumar B, Caneja C, Leaper C, Mann B, Samson A, Bhavsar PK, Boffito M, Johnson MR, Pozniak A, Pelly M; PIONEER trial group. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. Lancet Respir Med. 2022;S2213-2600(22)00412-X. https://doi.org/10.1016/S2213-2600(22)00412-X.

Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022. https://doi.org/10.1038/s41598-021-90551-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):489. https://doi.org/10.1186/s12879-021-06164-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozsurekci Y, Oygar PD, Gürlevik SL, Kesici S, Ozen S, Kurt Sukur ED, Gülhan B, Topaloglu R, Bayrakci B, Cengiz AB. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe? Pediatr Nephrol. 2021;36(11):3771–6. https://doi.org/10.1007/s00467-021-05111-x.

Article  PubMed  PubMed Central  Google Scholar 

Gök S, Bahçecioğlu ÖF, Durmuş M, Gün ZÜ, Ersoy Y, Aytemur ZA, Ulutaş Ö. The safety profile of favipiravir in COVID-19 patients with severe renal impairment. Int J Clin Pract. 2021;75(12):e14938. https://doi.org/10.1111/ijcp.14938.

Article  CAS  PubMed  Google Scholar 

McElvaney OJ, Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. https://doi.org/10.1038/s41591-021-01283-z.

Article  CAS  Google Scholar 

Acanfora D, Acanfora C, Ciccone MM, Scicchitano P, Bortone AS, Uguccioni M, et al. The cross-talk between thrombosis and inflammatory storm in acute and long-COVID-19: therapeutic targets and clinical cases. Viruses. 2021;13(10):1904. https://doi.org/10.3390/v13101904.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. https://doi.org/10.1038/s41591-021-01283-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501–8. https://doi.org/10.1016/j.ijid.2020.10.069.

Article  CAS  PubMed  Google Scholar 

Ueda M, Tanimoto T, Murayama A, Ozaki A, Kami M. Japan’s drug regulation during the COVID-19 Pandemic: lessons from a case study of Favipiravir. Clin Pharmacol Ther. 2022;111(3):545–7. https://doi.org/10.1002/cpt.2251.